Phase 1 and expanded imaging study of tozuleristide in patients with pediatric primary central nervous system tumors
Tozuleristide was well tolerated. The data suggest that tozuleristide fluorescence may be applicable in a range of pediatric CNS tumors and clinical scenarios, providing a useful adjunct to neurosurgeon experience in distinguishing tumor from nontumor tissue.
Authors
- Kimberly Starr (ORCID: https://orcid.org/0000-0002-0101-7969)
- Jeffrey J. Perry (ORCID: https://orcid.org/0000-0003-2134-9597)
- Julia Parrish-Novak (ORCID: https://orcid.org/0000-0003-4958-0782)
- Sandra L. Poliachik
- Sarah Leary (ORCID: https://orcid.org/0000-0003-0225-6184)
- Carolyn Gombotz
- Bonnie Cole (ORCID: https://orcid.org/0000-0002-3471-1949)
- Jeffrey G. Ojemann (ORCID: https://orcid.org/0000-0001-7580-8934)
- Kristi Harrington
- Amy Lee (ORCID: https://orcid.org/0000-0001-6205-6614)
- Dennis M. Miller (ORCID: https://orcid.org/0000-0001-7923-7040)
- Laura Ishak
- David Kittle
- Stacey Hansen
Institutions
- Seattle Children's Hospital (US)
- University of Washington (US)
- Sherman Oaks Hospital (US)
- Fred Hutch Cancer Center (US)
- Blaze Bioscience (United States) (US)
- Seattle Children's Hospital (US)
- Center for Cancer and Blood Disorders (US)
- Neurological Surgery (US)
Publication Details
- Journal
- Journal of Neurosurgery Pediatrics
- Published
- 2025-08-30
- DOI
- https://doi.org/10.3171/2025.5.peds24630
- Citations
- 1
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.63